Detalles de la búsqueda
1.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Ann Oncol
; 33(6): 593-601, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35219776
2.
Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
Ann Oncol
; 33(3): 299-309, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34861374
3.
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Gynecol Oncol
; 163(3): 524-530, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34625284
4.
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Gynecol Oncol
; 161(1): 160-165, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33608144
5.
Dose and time effects of solar-simulated ultraviolet radiation on the in vivo human skin transcriptome.
Br J Dermatol
; 182(6): 1458-1468, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31529490
6.
Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
Gynecol Oncol
; 158(1): 47-53, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32381362
7.
The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients.
Gynecol Oncol
; 158(2): 431-439, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32451123
8.
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).
Gynecol Oncol
; 156(1): 45-53, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31836184
9.
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Gynecol Oncol
; 155(2): 186-191, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31519320
10.
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
Ann Oncol
; 29(3): 737-743, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29267856
11.
Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.
Ann Oncol
; 29(4): 910-916, 2018 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29415128
12.
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Ann Oncol
; 29(1): 154-161, 2018 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29045554
13.
Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
Gynecol Oncol
; 148(1): 79-85, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29157627
14.
Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy.
Eur J Cancer Care (Engl)
; 27(2): e12820, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29337398
15.
Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
Ann Oncol
; 28(11): 2733-2740, 2017 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29117336
16.
Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.
Ann Oncol
; 28(8): 1849-1855, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28595285
17.
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
Ann Oncol
; 28(4): 727-732, 2017 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27993805
18.
Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.
Ann Oncol
; 27 Suppl 1: i66-i71, 2016 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27141076
19.
Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study.
Ann Oncol
; 27(2): 332-8, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26578727
20.
The effect of pulmonary function testing on bleomycin dosing in germ cell tumours.
Intern Med J
; 46(8): 893-8, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27305276